Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1240 studies found for:    Open Studies | "Lymphoma"
Show Display Options
Rank Status Study
1 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
2 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: CD19-targeted CAR-T cells
3 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
4 Recruiting Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
5 Recruiting Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Condition: B-cell Lymphoma
Interventions: Drug: SD-101;   Radiation: Radiation therapy
6 Not yet recruiting A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Biological: SAIT101;   Biological: MabThera®
7 Not yet recruiting Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Condition: Lymphoma
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: Methotrexate
8 Recruiting CD19-targeting CAR T Cells for B Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Biological: CD19-targeting CAR T Cells infusion
9 Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
10 Recruiting CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Condition: Lymphomas
Intervention: Genetic: Anti-CD30 CAR T cells
11 Recruiting Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
Condition: Lymphoma
Intervention: Radiation: Radiation Therapy
12 Recruiting Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Pembrolizumab
13 Recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
14 Not yet recruiting A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Blinatumomab
15 Recruiting Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
Condition: Lymphoma
Interventions: Drug: Rituximab;   Radiation: Radiation
16 Recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
17 Recruiting Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: thiotepa;   Procedure: stem cell transplant;   Drug: G-CSF
18 Recruiting Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)
Condition: Lymphoma
Intervention:
19 Recruiting Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Intervention: Other: Any treatment, watch and wait policy included
20 Recruiting Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.